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Background: The ambulatory treatment of advanced heart failure (HF) with intermittent 
infusions of inotropes or natriuretic peptide chosen immediately before each infusion has not 
been described. 
Methods: Between May 2005 and July 2009, we treated 11 patients presenting with 
advanced HF, who received a total of 369 infusions of carperitide, olprinone, dopamine, or 
dobutamine, once or twice weekly. The pharmaceutical was selected before each infusion 
based on the systolic blood pressure (BP). 
Results: Carperitide, olprinone, and catecholamines were administered to 8 (73 infusions of 
0.030±0.004 μg/kg/min for 3.3±0.8 h), 4 (18 infusions of 0.070±0.017 μg/kg/min for 3.3±0.5 
h), and 6 patients (278 infusions of 3.6±1.9 μg/kg/min for 2.8±1.0 h), respectively. No 
adverse effect requiring cessation of infusion was observed. Over a mean follow-up of 
29.3±28.8 months (range: 2-104), 4 patients died, all from cardiac causes. The Kaplan-Meier 
cumulative survival rate was 69.3% at 20 months (median follow-up). Compared with the 
pre-infusion period, the duration and number of hospitalizations for management of HF were 
decreased by 73.9% (p=0.017), and 51.9% (p=0.007), respectively, during the treatment 
period, and the overall medical costs by 56.9% (p=0.021).  
Conclusions: In this study population, intermittent drug infusions selected from inotropes or 
natriuretic peptide based on the baseline systolic BP significantly decreased the length and 
  
3 
number of hospitalizations and costs, without increasing mortality. These results indicate that 






The rehospitalization of patients suffering from heart failure (HF) is associated with an 
increased risk of death [1]. Therefore, besides alleviating symptoms and enhancing the 
quality of life, the prevention of acute cardiac decompensation and hospitalizations is an 
important therapeutic objective, which might lower the long-term morbidity and mortality. 
The remote monitoring of body weight (BW) [2] and of intrathoracic impedance [3] have 
been found to anticipate the development of acute cardiac decompensation, and 
transtelephonic interventions to lower the rate of hospitalization for management of HF [4]. 
In spite of recent therapeutic progress, patients presenting with American College of 
Cardiology/American Heart Association (ACC/AHA) stage D HF remain at high risk of 
hospitalization and death [5]. In these patients, the only interventions known to improve 
outcomes, beyond standard management, are cardiac transplantation and left ventricular 
assist devices, which are limited by the availability of donor organs, or by hemorrhagic, 
thromboembolic, and infectious complications. Thus, the need persists to find other means of 
lowering the rates of hospitalization and death. 
Multiple studies have been published on the use of intermittent drug infusions in 
patients presenting with advanced HF [6-9]. While symptomatic improvements [6] and an 
increase in exercise tolerance [7] have been observed with inotropes, a retrospective analysis 
of the ADHERE registry found a significantly higher in-hospital mortality associated with the 
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short-term administration of dobutamine or milrinone, than with vasodilator therapy with 
nitroglycerin or nesiritide [10], suggesting that intermittent infusions of inotropes increase 
mortality [8]. On the other hand, in a randomized trial, infusions of a natriuretic peptide 
lowered neither mortality nor the rate of hospitalizations [9]. 
We have studied the intermittent infusions of drugs in patients presenting with 
advanced HF since 1995 [11]. In contrast to several other studies of intermittent infusions, 
which administered a single inotrope or natriuretic peptide [6-9], we choose among different 
drugs with each infusion, depending on the baseline systolic blood pressure (BP), a strategy 




We evaluated all patients who received intermittent drug infusions in our hospital between 
May 2005 and July 2009. To be included in this analysis, the patients had to fulfill all the 
following criteria before the beginning of intermittent infusion therapy: 1) ≥2 hospitalizations 
for management of HF within the previous 12 months, 2) symptoms consistent with New 
York Heart Association (NYHA) functional class III or IV, 3) optimally treated with oral and 
device therapy, 4) had granted a written informed consent to participate in the study. Patients 
were excluded from intermittent infusion therapy if they had suffered an acute myocardial 
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infarction within 3 months, or presented with a) unstable angina, b) an estimated glomerular 
filtration rate <15 ml/min/1.73 m
2
 or long-term dialysis, or c) pure right ventricular failure 
(e.g. primary pulmonary hypertension). 
 
Informed consent 
Written informed consent was obtained from all the participants of this study, and all
 
study 
procedures were in compliance with the Declaration of Helsinki and the institutional 
guidelines
 
of Hyogo Prefectural Amagasaki Hospital. 
 
Infusion therapy 
The drugs were administered intravenously for 3 or 4 h, once or twice weekly. The choices of 
drugs included a) the A-type natriuretic peptide, carperitide, b) olprinone, and c) dopamine or 
dobutamine. The pharmaceutical and infusion schedule were chosen by each individual 
physician. Carperitide was avoided when the systolic BP was <90 mmHg, and dopamine and 
dobutamine when the systolic BP was ≥110 mmHg. Boluses of furosemide were administered 
during the infusions as needed. The patients were hospitalized if HF worsened in spite of the 
twice-weekly infusions. 
To confirm the short-term safety and tolerance of therapy, the electrocardiogram, BP 
and urine output (UO) were monitored throughout the infusions. BW, systolic and diastolic 
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BP, heart rate (HR), and oxygen saturation were recorded at the beginning and end of each 
infusion. A patient was defined as a responder to therapy when the length and number of 
hospitalizations and costs were all decreased after, compared with before the intermittent 
infusions. To define pre-infusion period, we picked up all periods that patients were not 
hospitalized for >24 months, and the last one of those periods was defined as the start of 
pre-infusion period for each patient. In other words, pre-infusion period was defined so that 
each patient experienced ≥1 hospitalization within 24 months of previous hospitalization in 
the pre-infusion period. The end of the post-infusion period was July 2009 or death of the 
patient, whichever occurred earlier. 
 Left ventricular ejection fraction was measured echocardiographically, and 
calculated by the modified Simpson’s method. Diabetes mellitus was defined as a) a 
≥126-mg/dl fasting or >200-mg/dl non-fasting serum glucose, or b) use of an antidiabetic 
medication. Hypertension was defined as a) a ≥140-mmHg resting systolic or ≥90-mmHg 
diastolic BP,
 
or b) use of an antihypertensive medication. 
 
Statistical analysis 
The data are reported as means ± standard deviation (SD). To evaluate the long-term safety, 
survival curves were constructed by Kaplan-Meier method. To ascertain the effects of the 
intermittent infusions on medical costs, and on length and numbers of hospitalizations, we 
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compared the measurements made during the pre-infusion period with those in the 
post-infusion period. Continuous variables were compared by factorial analysis of variance, 
and dichotomous variables by chi-square analysis. The Wilcoxon’s signed-rank test was used 
to compare the monthly numbers and lengths of hospitalizations for management of HF, and 
the monthly costs incurred, before versus after the infusions. Student’s t-test was used to 
compare other data. The relationship between UO and other factors was examined by single 
and multiple variables linear regression analysis. Survival curves were constructed by the 
Kaplan-Meier method. A p value <0.05 was considered significant. 
 
Results 
Short-term effects of the infusions 
The baseline characteristics of the 11 patients enrolled in the study are shown in table 1. A 
total of 369 infusions were administered, and the short-term effects of each pharmaceutical 
infused are summarized in table 2. The infusion of carperitide decreased the systolic and 
diastolic BP significantly, while dopamine and dobutamine increased the systolic BP and HR 
significantly. Olprinone changed neither BP nor HR. BW was significantly lowered by all 
treatments. No adverse effect was observed, including arrhythmias or changes in blood 
pressure, requiring the cessation of drug infusion. 
By multiple linear regression analysis, using the variables listed in table 2, BW and 
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dose of intravenous furosemide were independent predictors of UO during the infusions 
(Table 3). 
 
Long-term survival of the study population 
Over a mean follow-up of 29.3±28.8 months (median = 20; range 2-104), 4 patients died, all 
from cardiac causes. By Kaplan-Meier analysis, the cumulative survival rate was 69.3% at 20 
months (median follow-up), and 55.4% at 22 months (Figure 1). 
 
Effects of treatment on costs and hospitalizations 
Comparing the mean pre-infusion period of 15.7±9.4 months with the post-infusion period of 
29.3±28.8 months (Figure 2), the mean duration of hospitalizations for management of HF 
was shortened from 6.9±3.0 to 1.8±1.5 days/month (73.9%; p=0.017), the mean number of 
hospitalizations decreased from 0.36±0.14 to 0.17±0.18 (51.9%; p=0.007), and the mean cost 
was lowered from 216±86 to 93±68 10
3
 yen (56.9%; p=0.021). 
 Among the 11 patients, 8 responded to the intermittent infusions treatment (Table 4). 
Compared with the non-responders, the patients who responded tended to have a greater 
baseline body mass index (p=0.12), slower HR (p=0.10), higher UO (p=0.15), and higher 





This is, to our knowledge, the first study of intermittent infusions for the management of HF, 
in which the pharmaceuticals administered, inotropes or natriuretic peptides, were chosen on 
the basis of the pre-treatment systolic BP. We found that this treatment strategy significantly 
decreased the length and numbers of hospitalizations, as well as overall medical costs. 
 Since our preliminary report [11], we have overcome several limitations by 
developing a system dedicated to the administration of intermittent infusion therapy, 
including the unlimited availability of beds in our ambulatory department. Furthermore, the 
longer duration of follow-up allowed a more reliable evaluation of the long-term safety of the 
treatment. 
 
Safety and efficacy of intermittent infusions 
The evaluation of the safety and efficacy of intermittent infusion therapy has not been 
standardized. On the short term, the UO, BP, HR, oxygen saturation, electrocardiogram and 
changes in BW should be monitored with each infusion. While these observations do not 
predictably correlate with clinical outcomes [12], they are essential in the evaluation of safety. 
On the long term, survival and length and number of hospitalizations for management of HF 
are the most important endpoints. Quality of life is another important endpoint, which was 
not measured in this retrospective study, as the pre-infusion data were not available. 
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As a consequence of an aging population and greater proportion of survivors of acute 
coronary syndromes and cardiac decompensation, the costs of care for patients suffering from 
HF are increasing. While the economic impact of intermittent infusions has not been 
published previously, lowering these costs is as important as decreasing the rates of 
hospitalization or lowering mortality. 
 
Selection of pharmaceuticals 
The effects of intermittent infusions of dopamine have not been examined in a randomized 
study. The randomized trials of dobutamine have been reviewed by Bayram et al., who found 
a trend toward a greater alleviation of symptoms and increase in exercise capacity conferred 
by dobutamine compared with placebo [8]. However, they recommended, when a safer 
option is available, avoiding the administration of intermittent dobutamine infusions, because 
of their potentially adverse effects on survival. 
Sanada et al. reported cardioprotective effects conferred by phosphodiesterase 
inhibitors [13], while Cesario et al. observed symptomatic improvements and decreased rates 
of hospitalization by the intermittent administration of low doses of milrinone [6]. However, 
the intermittent use of phosphodiesterase inhibitors has not been studied in a randomized 
trial.  
Natriuretic peptides are antagonistic to the hyperactivity of 
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renin-angiotensin-aldosterone system and promote reverse remodeling [14], therefore are 
expected to confer clinical benefits when used intermittently. However, intermittent infusions 
of nesiritide did not lower the risk of death or hospitalizations in a randomized trial [9]. 
Patients presenting with advanced HF are usually in a low-output, hypotensive state. The 
administration of vasodilators during this state might further promote hypotension and 
decrease the perfusion of central organs, which may explain the absence of effects conferred 
by the intermittent infusions of natriuretic peptide on survival or rate of hospitalizations. 
In all previous studies of intermittent infusions, the treatment was limited to a single 
drug, whether an inotrope or a natriuretic peptide. However, intermittent infusions of 
natriuretic peptide should be avoided in presence of low output or hypotensive state. 
Phosphodiesterase inhibitors or a catecholamine should be chosen instead and, in presence of 
severe low output or hypotensive state, a catecholamine may be the only choice. Furthermore, 
since, in the same patient, the vital signs may vary, a choice of drug before each infusion is 
likely to be associated with better outcomes. 
A simple, inexpensive and reliable indicator is needed to twice weekly optimize the 
drug selection for each infusion. Echocardiography or measurements of pulmonary capillary 
wedge pressure or bioimpedance [15] are very useful, though cannot be used because of their 
complexity and cost. At present, the easily measurable and nearly cost-free systolic BP is the 
only indicator that meets the requirements. Finally, the 2008 European Society of Cardiology 
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guidelines for the diagnosis and treatment of acute and chronic HF recommend a choice of 
pharmaceuticals guided by the systolic BP [16]. 
 The systolic BP below which natriuretic peptides should be avoided, or a 
catecholamine be used, has not been firmly established. Pending further studies, however, we 
believe that natriuretic peptides be avoided when the systolic BP is <90 mmHg, and 
dopamine or dobutamine when it is ≥110 mmHg, considering that we observed no adverse 
event in this study. 
In this study, we chose not continuous but intermittent infusions because of concern 
about arrhythmia or changes in blood pressure. However, intermittent infusions may have 
weaker effect than continuous infusions, and should be compared with continuous infusions 
in the future. 
 
Safety of intermittent infusions 
The main immediate adverse effects of intermittent infusion therapy are hypotension and 
arrhythmias. In a randomized trial of intermittent infusions of nesiritide, a higher rate of 
symptomatic and asymptomatic hypotension was reported in the actively treated than in the 
placebo-treated group [9]. On the other hand, no increase in arrhythmias has been reported 
with intermittent infusions of inotropes [8], and we observed neither hypotension nor an 
increase in arrhythmias during the infusions in this study. This short-term safety was achieved 
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by avoiding the administration of a) natriuretic peptides to patients presenting with 
hypotension, b) catecholamine whenever possible, c) high doses of pharmaceuticals.  
The cumulative survival of our study population was 55.4% at 22 months. The 
survival rate of patients presenting with HF varies with the severity of disease, the age and 
race of the patient, and other factors. In absence of a large Japanese registry such as 
ADHERE [10], we found a study of Japanese patients suffering from advanced HF with 
similar clinical characteristics, including NYHA functional class III or IV, brain natriuretic 
peptide >170 pg/ml, 70% treated with an angiotensin-converting enzyme inhibitor, and 28% 
with a beta-adrenergic blocker [17]. Although these patients (63.6±1.5 years of age) were, on 
average, younger than ours (71.0±8.4 years), their survival rate was about 55% at 
approximately 600 days. Therefore, the intermittent infusions do not appear to have increased 
the mortality rate, which is acceptable, considering the severity of our patients’ clinical 
presentation. 
 
Response to therapy 
Out of our 11 patients, 3, who did not respond to the intermittent infusions, tended to have a 
lower baseline body mass index, faster HR, lower UO, and lower systolic BP. However, we 
couldn’t find any predictor of response to intermittent infusion therapy in this small study 
population, and larger studies are warranted to determine the predictor. 
  
15 
Systolic BP may be a predictor of the response because low systolic BP was a 
predictor of hospitalization within 1 month after the ambulatory administration of an 
intravenous diuretic [18]. Furthermore, a low systolic BP has been associated with adverse 
clinical events in acute [19] and in chronic [20] HF. 
 Body mass index may also be a predictor of response to intermittent infusion therapy. 
Cardiac cachexia is common in chronic HF and a predictor of poor outcome [21]. Although 
the definition of cardiac cachexia has not been standardized [21], the prognosis of patients 
presenting with chronic HF and a low body mass index is poor [22]. 
 HR is reported to the independent risk factor of poor cardiac function and in-hospital 
death after acute myocardial infarction [23], and may be used as a marker of the autonomic 
nervous activity in patients with chronic heart failure [24]. However, the prognostic power of 
HR in HF remains undetermined. It was found to be an independent predictor of HF in one 
previous study [25], however not in another [20]. 
Diuretics activate the renin-angiotensin-aldosterone system in patients suffering from 
chronic HF, who are at risk of renal dysfunction and dehydration [16]. However, in that study, 
the UO of responders during the infusions tended to be greater, after adjustment for BW, and 
the dose of furosemide and BW were both independent predictors of UO during the infusions. 
In addition, the ambulatory administration of intravenous diuretics decreases the rate of 
hospitalizations for management of HF [18]. Therefore, the addition of intravenous 
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furosemide to the infusions may have increased the benefits conferred by the infusions of 
inotropes or natriuretic peptide. However, the optimal dose of furosemide remains to be 
determined. 
 
Limitations of our study 
In this study, which included a small patient population from a single institution, the effect of 
infusion therapy on hospitalizations and costs was assessed by comparison with pre-infusion 
periods of the same patients instead of control-group. Accordingly a larger, double-blind, 
multicenter trial is warranted. Moreover, because we didn’t perform invasive hemodynamic 
measurement during infusions or at systematically planned timing, pulmonary capillary 
wedge pressure or cardiac output could not be assessed in this study. Further, because of 
concern about arrhythmia or changes in blood pressure, we chose not continuous but 
intermittent infusions, which might decrease the effect of infusions.  
 
Conclusion 
This is the first study of intermittent infusion therapy, in which inotropes or a natriuretic 
peptide were administered on the basis of the pre-treatment systolic BP. In 11 patients 
presenting with advanced HF, the infusions significantly decreased a) the length and rate of 
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Figure 1. Cumulative survival rates of the 11 patients 
Over a mean follow-up of 29.3±28.8 months (median = 20; range 2-104), 4 patients died. The 
cumulative survival rate was 69.3% at 20 months (median follow-up), and 55.4% at 22 
months. 
 
Figure 2. Effects of infusion therapy on the medical costs and length of hospitalizations 
Comparing the pre-infusion period (15.7±9.4 months) with the post-infusion period 
(29.3±28.8 months), the infusions significantly decreased the length and number of 

























































































































































































































































































































Table 1 Baseline characteristics of the 11 study patients 
Age, years  
Men/women 
Ischemic heart disease  
Left ventricular ejection fraction, % 






Atrial fibrillation or flutter 
Serum creatinine, mg/dl 
Estimated glomerular filtration rate, ml/min/1.73m
2
 
Blood urea nitrogen, mg/dl 
Sodium, mmol/l 
Systolic blood pressure, mmHg 
Heart rate, bpm 
Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker 
Beta-adrenergic blocker 
Aldosterone antagonist 
Days of hospitalizations* per month before infusions 
Number of hospitalizations* per month before infusions  
























Values are means ± SD, or numbers (%) of patients 
*for management of heart failure 
 
Table 1
Table 2 Characteristics and short-term effects of each infusion 
 Carperitide 
(n=8 patients, 73 
infusions) 
Olprinone 
(n=4 patients, 18 
infusions) 
Catecholamine 





Urinary output, ml 
Body weight, kg 
Before infusion 
After infusion 




Diastolic   
Before infusion 
After infusion 
Heart rate, bpm  
Before infusion 
After infusion 































































* p<0.0001 vs. before infusion. 
Table 2
Table 3 Correlates of urinary output during infusions 
 Analysis  
 Single variable p Multiple variable p 
Body weight before infusion, kg 
Blood pressure before infusion, mmHg  
Systolic 
Diastolic  
Heart rate before infusion, bpm 

























Values are regression coefficients (95% confidence intervals). 
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